Emergent gets $56M ACAM2000 contract modification; 2025 sales projected >$120M

Emergent BioSolutions Inc.

Contract Modification No. 14 valued at $56M; deliveries to U.S. government by Dec 31, 2025.
Total 2025 projected sales for ACAM2000 and ancillary products exceed $120M from diverse customer base.
ACAM2000 is FDA-approved for smallpox (2007) and mpox (Aug 2024); also licensed in Canada, Australia, Singapore.
Modification exercises Option Year 6 under existing 10-year ASPR contract (75A50119C00071).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.